pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,467 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT967Endpoints742BioPharma Dive283BioSpace181Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5626Rare Disease1252Cardiology1054Hematology940Immunology934Vaccines816Pulmonology
  • Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
    Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
    onclive · 3mo ago↗ source
  • Supreme Court temporarily extends women’s access to a widely used abortion pill
    The Supreme Court is temporarily extending access to a widely used abortion pill while it considers whether to allow restrictions on the drug to take effect.
    STAT · 3mo ago↗ source
  • STAT+: Colombia wins a key court ruling over a compulsory license issued for an HIV medicine
    A South American court upheld the steps taken by the Colombian government when it issued a compulsory license two years ago for an HIV medicine.
← prev
page 49 of 59
next →
65
fda recalls41
fda medwatch32
fda press25
783
Psychiatry & CNS691
Ophthalmology347
Endocrinology & Metabolism342
Pain342
Infectious Disease331
STAT · 3mo ago
↗ source
  • Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
    Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
    onclive · 3mo ago↗ source
  • STAT+: Trump pivots on kratom derivative 7-OH, floating approval for some forms
    Last year, the FDA had warned that natural opioids in kratom were being turned into harmful products. Now President Trump says approval should be considered.
    STAT · 3mo ago↗ source
  • STAT+: Medicare’s miss on Alzheimer’s drug spending
    Far fewer seniors than expected are taking costly Alzheimer's drugs.
    STAT · 3mo ago↗ source
  • No FDA permission, no problem: New flavored vape policy worries experts
    A new FDA policy will let some flavored vapes stay on the market without authorization.
    STAT · 3mo ago↗ source
  • MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
    Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.
    onclive · 3mo ago↗ source
  • INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC
    First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.
    onclive · 3mo ago↗ source
  • Treatment Intensification Gains Momentum in mCSPC Management
    During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.
    onclive · 3mo ago↗ source
  • STAT+: Astellas treatment offers new hope to a devastated rare disease community
    Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
    STAT · 3mo ago↗ source
  • FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations
    Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.
    onclive · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
    People on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipated
    STAT · 3mo ago↗ source
  • Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
    R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.
    onclive · 3mo ago↗ source
  • Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection
    In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma.
    onclive · 3mo ago↗ source
  • Expanding ctDNA Applications to RCC and Germ Cell Tumors
    Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.
    onclive · 3mo ago↗ source
  • RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
    Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.
    onclive · 3mo ago↗ source
  • ctDNA in Metastatic Urothelial Carcinoma
    Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.
    onclive · 3mo ago↗ source
  • Institutional Perspectives on Treatment Thresholds in PLGG
    Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.
    onclive · 3mo ago↗ source
  • Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups
    In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across different IMDC…
    onclive · 3mo ago↗ source
  • The connection between periods and mental health
    Plans to oust Makary, a looming Supreme Court deadline on mifepristone, and other health news from Morning Rounds
    STAT · 3mo ago↗ source
  • STAT+: Five years after disaster, a rare disease community gets new chance at treatment
    Some boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.
    STAT · 3mo ago↗ source
  • Opinion: What addiction medicine can teach us about depending on AI
    People gradually rely on AI to reduce the discomfort of thinking. For some, that can become a problem.
    STAT · 3mo ago↗ source
  • Opinion: AI doctors should be licensed. Here’s a framework to do that
    A state-by-state approach to clinical AI won’t work. Here’s a framework that can.
    STAT · 3mo ago↗ source
  • STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
    Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.
    STAT · 3mo ago↗ source